• Sirona Biochem (SBM) receives antiviral testing results for its antiviral library of compounds
  • The centre screened around 20 compounds produced at Sirona’s subsidiary TFChem
  • six compounds showed antiviral activity, with one of particular interest
  • So far, the team at TFChem is set to expand the library to add five to 10 new compounds
  • Testing is scheduled to begin in the next two months
  • Sirona Biochem (SBM) is up 5 per cent, trading at C$0.10 at 11:13 am EST

Sirona Biochem (SBM) received results from its research collaboration with the International Centre for Genetic Engineering and Biotechnology to advance Sirona’s antiviral library of compounds.

Established in 1983, ICGEB is an independent intergovernmental organization with HQ in Trieste (Italy) and with additional laboratories in New Delhi (India) and Cape Town (South Africa).

Results from the test

The centre screened around 20 compounds produced at Sirona’s subsidiary TFChem as potential inhibitors of SARS-CoV-2 using specialized assays developed at the centre.

As for work, it was performed at the Laboratory of Molecular Virology located in Trieste, Italy, under the direction of Dr. Alessandro Marcello, an internationally recognized expert in Human Virology.

Of the 20 compounds, six showed antiviral activity, with one of particular interest.

Based on these results, the team at TFChem will expand the library to add five to 10 new compounds.

Looking forward, Sirona’s agreement with the ICGEB will be extended to test these new molecules. Testing is scheduled to begin in the next two months.

After receiving the “promising” results, Dr. Geraldine Deliencourt-Godefroy, Chief Scientific Officer, looks forward to more work.

“In all of our projects, the lead molecules resulted from modifications to earlier versions which is normal in the drug discovery process.”

“We remain [positive about generating] a new antiviral compound to fight SARS-CoV-2 and many other viruses. We strongly believe we are on the right track and will continue this project accordingly,” concluded Dr. Deliencourt-Godefroy.

The company will continue to update the public as projects change and develop.

Sirona Biochem is a cosmetic ingredient and drug discovery company with proprietary platform technology.

Sirona Biochem (SBM) is up 5 per cent, trading at C$0.10 at 11:13 am EST.


More From The Market Online

Metals Creek hits visible gold at Shabaqua Corners Gold Project

Metals Creek Resources (TSXV:MEK) reveals drill results for the Shabaqua Corners Gold Property in Ontario.

Why Decisive Dividend stock lets you have your cake and eat it too

Acquisition-oriented company Decisive Dividend Corp. (TSXV:DE) announces a monthly dividend of C$0.045 per common share for July 2024.

Bragg Gaming continues global expansion, teams with Kingsbet

Bragg Gaming Group (TSX:BRAG) launches its full turnkey solution with Czech land-based casino operator Kings Entertainment A.S.